2023 ICD-10-CM Diagnosis Code D46.9

New Call-to-action

Myelodysplastic syndrome, unspecified

    2016 2017 2018 2019 2020 2021 2022 2023 Billable/Specific Code
  • D46.9 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
  • The 2023 edition of ICD-10-CM D46.9 became effective on October 1, 2022.
  • This is the American ICD-10-CM version of D46.9 - other international versions of ICD-10 D46.9 may differ.
Applicable To
  • Myelodysplasia NOS
The following code(s) above D46.9 contain annotation back-references
Annotation Back-References
In this context, annotation back-references refer to codes that contain:
  • Applicable To annotations, or
  • Code Also annotations, or
  • Code First annotations, or
  • Excludes1 annotations, or
  • Excludes2 annotations, or
  • Includes annotations, or
  • Note annotations, or
  • Use Additional annotations
that may be applicable to D46.9:
  • C00-D49
    2023 ICD-10-CM Range C00-D49


    • Functional activity
    • All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
    • Morphology [Histology]
    • Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
    • Primary malignant neoplasms overlapping site boundaries
    • A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
    • Malignant neoplasm of ectopic tissue
    • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
  • D37-D48
    2023 ICD-10-CM Range D37-D48

    Neoplasms of uncertain behavior, polycythemia vera and myelodysplastic syndromes

    • Categories D37-D44, and D48 classify by site neoplasms of uncertain behavior, i.e., histologic confirmation whether the neoplasm is malignant or benign cannot be made.
    Type 1 Excludes
    • neoplasms of unspecified behavior (D49.-)
    Neoplasms of uncertain behavior, polycythemia vera and myelodysplastic syndromes
  • D46
    ICD-10-CM Diagnosis Code D46

    Myelodysplastic syndromes

      2016 2017 2018 2019 2020 2021 2022 2023 Non-Billable/Non-Specific Code
    Type 2 Excludes
    • drug-induced aplastic anemia (D61.1)
    Use Additional
    • code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)
    Myelodysplastic syndromes
Approximate Synonyms
  • High grade myelodysplastic syndrome lesions
  • Low grade myelodysplastic syndrome lesions
  • Myelodysplastic syndrome
  • Myelodysplastic syndrome (clinical)
Clinical Information
  • (mye-eh-lo-dis-plas-tik sin-drome) disease in which the bone marrow does not function normally.
  • A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the who guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (who, 2001)
  • A disorder characterized by insufficiently healthy hematapoietic cell production by the bone marrow.
  • A group of diseases in which the bone marrow does not make enough healthy blood cells.
  • Abnormal bone marrow cells that may lead to myelogenous leukemia.
  • Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into acute myeloid leukemia.
  • Your bone marrow is the spongy tissue inside some of your bones, such as your hip and thigh bones. It contains immature cells, called stem cells. The stem cells can develop into the red blood cells that carry oxygen through your body, the white blood cells that fight infections, and the platelets that help with blood clotting. If you have a myelodysplastic syndrome, the stem cells do not mature into healthy blood cells. This leaves less room for healthy cells, which can lead to infection, anemia, or easy bleeding.myelodysplastic syndromes often do not cause early symptoms and are sometimes found during a routine blood test. If you have symptoms, they may include
    • shortness of breath
    • weakness or feeling tired
    • skin that is paler than usual
    • easy bruising or bleeding
    • pinpoint spots under the skin caused by bleeding
    • fever or frequent infections
    myelodysplastic syndromes are rare. People at higher risk are over 60, have had chemotherapy or radiation therapy, or have been exposed to certain chemicals. Treatment options include transfusions, drug therapy, chemotherapy, and blood or bone marrow stem cell transplants. nih national cancer institute
ICD-10-CM D46.9 is grouped within Diagnostic Related Group(s) (MS-DRG v40.0):
  • 811 Red blood cell disorders with mcc
  • 812 Red blood cell disorders without mcc

Convert D46.9 to ICD-9-CM

Code History
  • 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
  • 2017 (effective 10/1/2016): No change
  • 2018 (effective 10/1/2017): No change
  • 2019 (effective 10/1/2018): No change
  • 2020 (effective 10/1/2019): No change
  • 2021 (effective 10/1/2020): No change
  • 2022 (effective 10/1/2021): No change
  • 2023 (effective 10/1/2022): No change
Code annotations containing back-references to D46.9:
  • Code Also: D47.02
    ICD-10-CM Diagnosis Code D47.02

    Systemic mastocytosis

      2018 - New Code 2019 2020 2021 2022 2023 Billable/Specific Code
    Applicable To
    • Indolent systemic mastocytosis
    • Isolated bone marrow mastocytosis
    • Smoldering systemic mastocytosis
    • Systemic mastocytosis, with an associated hematological non-mast cell lineage disease (SM-AHNMD)
    Code Also
    • , if applicable, any associated hematological non-mast cell lineage disease, such as:
    • acute myeloid leukemia (C92.6-, C92.A-)
    • chronic myelomonocytic leukemia (C93.1-)
    • essential thrombocytosis (D47.3)
    • hypereosinophilic syndrome (D72.1)
    • myelodysplastic syndrome (D46.9)
    • myeloproliferative syndrome (D47.1)
    • non-Hodgkin lymphoma (C82-C85)
    • plasma cell myeloma (C90.0-)
    • polycythemia vera (D45)
    Type 1 Excludes
    • aggressive systemic mastocytosis (C96.21)
    • mast cell leukemia (C94.3-)
  • Type 1 Excludes: D72
    ICD-10-CM Diagnosis Code D72

    Other disorders of white blood cells

      2016 2017 2018 2019 2020 2021 2022 2023 Non-Billable/Non-Specific Code
    Type 1 Excludes

Diagnosis Index entries containing back-references to D46.9:

ICD-10-CM Codes Adjacent To D46.9
D46.1 Refractory anemia with ring sideroblasts
D46.2 Refractory anemia with excess of blasts [RAEB]
D46.20 Refractory anemia with excess of blasts, unspecified
D46.21 Refractory anemia with excess of blasts 1
D46.22 Refractory anemia with excess of blasts 2
D46.A Refractory cytopenia with multilineage dysplasia
D46.B Refractory cytopenia with multilineage dysplasia and ring sideroblasts
D46.C Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality
D46.4 Refractory anemia, unspecified
D46.Z Other myelodysplastic syndromes
D46.9 Myelodysplastic syndrome, unspecified
D47 Other neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue
D47.0 Mast cell neoplasms of uncertain behavior
D47.01 Cutaneous mastocytosis
D47.02 Systemic mastocytosis
D47.09 Other mast cell neoplasms of uncertain behavior
D47.1 Chronic myeloproliferative disease
D47.2 Monoclonal gammopathy
D47.3 Essential (hemorrhagic) thrombocythemia
D47.4 Osteomyelofibrosis
D47.Z Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.